Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193310 | 0.73 | MAPT (0.47) | EGLN1IP6K1MAPTKDM4EALDH1A1 | |
| SCHEMBL1192410 | 0.70 | MAPT (0.51) | EGLN1QPCTMAPTKDM4EALDH1A1 | |
| SCHEMBL30449726 | 0.68 | EGLN1 (0.46) | EGLN1QPCTMAPTKDM4EALDH1A1 | |
| SCHEMBL30450337 | 0.67 | MAPT (0.41) | EGLN1QPCTMAPTKDM4EALDH1A1 | |
| SCHEMBL2968786 | 0.66 | ALDH1A1 (0.50) | EGLN1S1PR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL29699400 | 0.66 | CACNA2D1 (0.48) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL30449900 | 0.66 | EGLN1 (0.44) | EGLN1QPCTMAPTKDM4EALDH1A1 | |
| SCHEMBL23122450 | 0.65 | IP6K1 (0.60) | IP6K1QPCTMAP3K8MEN1KMT2A | |
| SCHEMBL20089105 | 0.65 | IP6K1 (0.57) | IP6K1MAP3K8MAPTKDM4EALDH1A1 | |
| SCHEMBL27517100 | 0.65 | IP6K1 (0.64) | IP6K1DRD2QPCTMAP3K8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | disclosed |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-01 | — | — | US | disclosed |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-02 | — | — | US | disclosed |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | disclosed |
| US-20160168127-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | US | disclosed |
| US-9073923-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-07 | — | — | US | disclosed |
| EP-2294066-B9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-11 | — | — | EP | disclosed |
| US-8865713-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| EP-2294066-B1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8759345-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-01-02 | — | — | US | disclosed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 10/4885IP6K1 3342/4885DRD2 4384/4885 |
| US-20180022733-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
| US-20140256722-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
| US-20160168127-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 8/4885IP6K1 3217/4885DRD2 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.